Robert Baird reiterates its Outperform rating on BioMarin Pharmaceutical (Nasdaq: BMRN) and sets a $44 price target, citing management's upbeat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE